Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > COMMENTARY
COMMENTARY
- METI Reports on “Patent Box”Taxation System in Its Vision 2010
July 5, 2010
- How Will Generics-Only Companies Will Compete with Major New Entrants?
June 28, 2010
- Mr Hasegawa Calls For Cooperation with Asian Countries
June 21, 2010
- PMDA Consultation for Clinical Drug Development in Japan
April 26, 2010
- Taiyo Needs to Restart from Scratch
April 19, 2010
- Drug Companies Have No Time to Lose under New Pricing System
March 29, 2010
- Wholesalers, Pharmacy Chains to Ally to Improve Their Business
March 22, 2010
- New Pricing System Gives Makers Good Chance to Break from Old Business Practices
March 8, 2010
- Transfer Limited Financial Resources to Parties Who Make Effort to Provide Better Services
March 1, 2010
- Korosho Moves to Change Its Vaccine Policy
February 22, 2010
- Prospects of the Japanese Pharmaceutical Industry in 2010
February 15, 2010
- Number of Entrants into Market for Biosimilars Increases, But Barriers Are Still High
February 8, 2010
- New Pricing System to Make e-Detailing More Important
February 1, 2010
- Number of Holders of Designated Disease Treatment Beneficiary Certificate Up to 647,604
November 30, 2009
- Verify Acceptability of Prices before Revising Pricing Rule
November 30, 2009
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics （２）
November 2, 2009
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics （１）
November 2, 2009
- How Not to License a Drug into Japan
October 12, 2009
- TOPICS／Abbott Named One of the "Best Places to Launch a Career" by BusinessWeek
October 5, 2009
- NHI Drug Pricing System Reform Becomes Further Unpredictable Following Gov't Change
October 5, 2009
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…